

Æterna Zentaris

INVESTOR FACT SHEET

Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage drug development company specialized in oncology and endocrinology.

INVESTMENT HIGHLIGHTS

<ul style="list-style-type: none"> ▪ One product on the market – Cetrotide® ▪ Two drugs in three Phase 3 trials – perifosine and Solorel™ ▪ Two Phase 3 trials with SPA, Fast Track review and EMA SA granted – perifosine ▪ One drug in Phase 2 trials – AEZS-108 	<ul style="list-style-type: none"> ▪ Six Orphan Drug designations granted ▪ NDA filing for Solorel™ expected in 2011 ▪ NDA filing for perifosine expected in 2012 ▪ Solid cash position
--	---

ROBUST AND BALANCED PIPELINE

Drug Discovery	Preclinical Trials	Phase 1	Phase 2	Phase 3	Marketed
~ 120,000 compound library	AEZS-120 Prostate cancer vaccine (oncology) AEZS-129, 131 and 132 Erk & PI3K Inhibitors (oncology) AEZS-127 ErPC (oncology) AEZS-123 Ghrelin receptor antagonist (endocrinology)	AEZS-112 (oncology) AEZS-130 Therapeutic in cancer cachexia / others (endocrinology)	Perifosine <ul style="list-style-type: none"> ▪ Multiple cancers AEZS-108 <ul style="list-style-type: none"> ▪ Ovarian cancer ▪ Endometrial cancer 	Perifosine <ul style="list-style-type: none"> ▪ Multiple myeloma ▪ Colorectal cancer AEZS-130 (Solorel™) <ul style="list-style-type: none"> ▪ Diagnostic in adult growth hormone deficiency (endocrinology) 	Cetrotide® <i>In vitro</i> fertilization
Partners			Perifosine: Keryx North America Handok Korea	Perifosine: Keryx North America Handok Korea	Cetrotide®: Merck Serono World ex-Japan Nippon Kayaku / Shionogi Japan

DRUG DEVELOPMENT PRIORITIES

Perifosine, is an orally active PI3K/Akt pathway inhibitor in two Phase 3 registration trials, one in multiple myeloma (“MM”) and the other in refractory advanced colorectal cancer (“CRC”), each of which is conducted and sponsored by Keryx Biopharmaceuticals, Inc. (“Keryx”), our partner and licensee for perifosine for North America, under a Special Protocol Assessment (“SPA”) reached with the FDA, which has also granted perifosine Orphan Drug status in MM and Fast Track designations in both indications. Perifosine has also been granted Orphan Drug status in neuroblastoma from the FDA and orphan medicinal product designation from the European Medicines Agency (“EMA”) in MM. In addition, perifosine has received positive advice from the EMA for both the MM and CRC programs, which means that the ongoing Phase 3 trials in these indications are expected to be sufficient for registration in Europe. Perifosine currently is also in multiple Phase 1 and 2 clinical studies, including renal cell cancer, pediatric cancer and various other cancers.

AEZS-108, represents a new targeting concept in oncology leading to personalized medicine, using a cytotoxic peptide conjugate, which is a hybrid molecule composed of a synthetic peptide carrier and a well known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH receptor-positive tumors. Ongoing Phase 2 trials, in advanced endometrial cancer and advanced ovarian cancer have met their predefined primary efficacy endpoints. Positive results for the Phase 2 trial in ovarian cancer, for which the FDA has granted Orphan Drug status, were disclosed last June at the ASCO annual meeting, while results in endometrial cancer are expected by year-end.

AEZS-130, a growth hormone (“GH”) secretagogue, is a novel synthetic small molecule acting as a ghrelin agonist that is orally active and stimulates the secretion of GH. A pivotal Phase 3 trial was initiated in the U.S. to investigate its safety and efficacy as a GH stimulation test for the diagnosis of adult GH deficiency (“AGHD”) for which Orphan Drug designation has been granted by the FDA. In addition to the diagnostic indication, AEZS-130, based on results of Phase 1 studies, has potential applications for the treatment of cachexia, a condition frequently associated with severe chronic diseases such as cancer, chronic obstructive pulmonary disease and AIDS. The trade name of AEZS-130 as a diagnostic test is Solorel™.



2010 MILESTONES

Perifosine

- Enrollment progression for the pivotal Phase 3 trial in multiple myeloma (“MM”) and metastatic colorectal cancer (“CRC”)
- Phase 1/2 results in MM, CRC, pediatric solid tumors and other cancers
 - ✓ Positive CRC and pediatric study results presented at last ASCO meeting in June 2010
- European and Asian development and registration strategy
 - ✓ Positive scientific advice obtained from EMA in MM and CRC; no additional studies required in EU for either indication

AEZS-108

- Final Phase 2 results in advanced ovarian and endometrial cancer
 - ✓ Positive ovarian cancer final results presented at last ASCO
- Initiation of additional clinical studies
 - ✓ US IND approved
 - Bladder cancer
 - Prostate cancer
 - Pancreatic cancer
 - Ovarian and endometrial cancer

AEZS-130

- Completion of Phase 3 trial as diagnostic test for AGHD
- Development and registration strategy update:
 - Rest of the world as diagnostic test for adult and pediatric GH deficiency
 - Explore potential for therapeutic use

FINANCIAL DATA

Market data as at August 4, 2010	NASDAQ	TSX
Closing price	US\$1.18	C\$1.21
Total common shares outstanding	83.1 million	83.1 million
Market capitalization	US\$98 million	C\$101 million

SELECTED FINANCIAL INFORMATION (UNAUDITED)

(in millions of US\$)	AS AT AND FOR THE THREE MONTHS ENDED		AS AT AND FOR THE TWELVE MONTHS ENDED	
	JUNE 30, 2010	JUNE 30, 2009	DECEMBER 31, 2009	DECEMBER 31, 2008
Revenues	5.6	8.4	63.2	38.5
R&D costs, net	5.0	12.1	43.8	57.1
Net loss	(4.4)	(13.0)	(24.7)	(59.8)
Cash, cash equivalents and short-term investments	45.3	56.8	38.1	49.7

CONTACT

FOR INFORMATION OR TO RECEIVE AN INVESTOR PACKAGE:

Please contact Ginette Vallières
 Phone: 418-652-8525, ext.: 265
gvallieres@aezsinc.com

Æterna Zentaris Inc.
 1405 du Parc-Technologique Blvd.
 Québec, Québec, CANADA
 G1P 4P5
www.aezsinc.com

NOTE & DISCLOSURES

This document contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause Æterna Zentaris’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability for the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are required to do so by a governmental authority or applicable law.